Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enoxaparin prophylactic vs therapeutic dosing in hospitalized COVID-19 pneumonia
2020-002214-40Phase 3Terminated
- Sponsor
- ASST Fatebenefratelli Sacco
- Start
- Oct 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3 trial of enoxaparin in coronavirus pneumonia and coronavirus disease 2019 (COVID-19) (2 arms), sponsored by ASST Fatebenefratelli Sacco. Primary endpoints: Mortality during hospitalization, Mortality at 1 month and 1 more. Started Oct 2021; status: terminated.
02
Drugs
enoxaparin
03
Conditions
coronavirus pneumoniacoronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-002214-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002214-40.